Human Longevity, Inc. (HLI), a genomics-based, technology-driven company working to revolutionize the practice of medicine, has announced several key promotions and additions to the company's senior leadership team.
Kenneth Bloom, M.D., will now assume the role of president of HLI. Bloom joined the company to head the oncology product area and to oversee laboratory operations. He will continue to oversee these areas and will lead all product development and commercialization as well as laboratory functions and operations. He reports directly to J. Craig Venter, Ph.D., HLI co-founder and CEO.
Dr. Bloom has more than 30 years of clinical and business experience and has been an early adopter and big proponent of information technology to revolutionize pathology and other areas of medicine. He is also a prolific and renowned researcher and lecturer in pathology, cancer, telemedicine, and informatics. He comes to HLI most recently from GE Healthcare where he was since 2011 as chief medical officer, In Vitro Diagnostics, life sciences. There he had oversight of Medical Affairs, Clinical Pathology Services, Pharma Pathology Services, Bioinformatics and R&D. He was also president and CEO of Clarient Pathology Services, the professional group contracted to provide pathology services to Clarient Diagnostic Services and SeqWright. In these roles he led the overall development and execution of the medical and scientific strategy, aligning them with the overall GE mission and business strategy.
Ashley Van Zeeland, Ph.D., who joined HLI after the company's acquisition of Cypher Genomics, will now serve as chief technology officer. In this role, she will lead the development and commercialization of all software and database products and continue to enhance and refine the commercial genomic pipeline for HLI. Since joining HLI in November, Van Zeeland has been focused on leading the pediatric and rare disease group at HLI as well as integrating the Cypher software into HLI.
Dr. Van Zeeland joined HLI was co-founder and CEO at Cypher Genomics. Prior to founding Cypher Genomics, she served as director, Strategic Partnerships, at the Scripps Translational Science Institute where she focused on novel public-private partnerships to accelerate translational research. Before transitioning to her role as Director, Strategic Partnerships she was a research fellow at the Scripps Translational Science Institute working on multiple projects leveraging human genome sequencing to identify disease causative variants and biomarker signatures for various conditions.
Tom Wamberg has joined HLI as president of the company's Insurance and Corporate Business Group. In his role, he will shape and direct HLI products such as whole genome and whole exome reports, as well as the HLI Health Nucleus, as offerings that insurance companies can bring to their clients. He will also be working with self-insured companies to offer whole genome, whole exome and Health Nucleus as benefits to their employees.
In his 30-year career, Wamberg has built and led numerous financial and professional insurance services businesses. Wamberg comes to HLI most recently from Uniphy Health, a secure healthcare collaboration platform for physicians, a company he co-founded in 2013 and where he remains its chairman. He previously started and led as chairman and CEO two other consulting companies, Clark & Wamberg, LLC and Clark Inc. Wamberg is a member of the American College of Healthcare Executives, and is a past president of the Association for Advanced Life Underwriting.